CDX
NCI-H460
Tumor indication
Lung
Description
NCI-H460 (Lung Cancer CDX Model)
The NCI-H460 line was derived from a patient with large cell lung carcinoma, a subtype of non-small cell lung cancer (NSCLC). It carries KRAS and STK11 mutations, reflecting clinically relevant drivers of lung cancer. NCI-H460 has been widely used in biomarker and therapeutic research. Its stability supports translational oncology studies.
Key Features:
- Derived from large cell lung carcinoma (NSCLC).
- KRAS and STK11 mutations.
- Represents aggressive lung cancer biology.
- Tumorigenic in xenograft models.
Applications:
NCI-H460 is applied in NSCLC drug discovery and biomarker validation. Researchers use it to evaluate KRAS-targeted and combination therapies. It is frequently employed in studies of drug resistance and lung cancer progression. Its reproducibility ensures reliable preclinical outcomes.
Details
- Tumor indication
- Lung
- Organism
- Human
- Mouse sex
- Female
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.